News - nivolumab

Filter

Current filters:

nivolumab

Popular Filters

Bristol-Myers Ph III nivolumab trial stopped early on good results

Bristol-Myers Ph III nivolumab trial stopped early on good results

25-06-2014

Shares of US pharma major Bristol-Myers Squibb rose 2.6% to $49.55 in post-market trading on June 25,…

Bristol-Myers SquibbnivolumabOncologyPharmaceuticalResearch

Immunotherapies show promise for non-small cell lung cancer market

Immunotherapies show promise for non-small cell lung cancer market

13-06-2014

Immunotherapies have huge potential for the treatment of non-small cell lung cancer (NSCLC), with three…

BiotechnologyBristol-Myers SquibbMarkets & MarketingMerck & ConivolumabOncologypembrolizumabResearchRoche

ASCO 2014: Strong results for Bristol-Myers Yervoy, and combo with nivolumab

ASCO 2014: Strong results for Bristol-Myers Yervoy, and combo with nivolumab

02-06-2014

Among the latest important research results presented at the 2014 prestigious annual meeting of the American…

Bristol-Myers SquibbnivolumabOncologyPharmaceuticalResearchYervoy

Bristol-Myers and Incyte sign up to evaluate combo regimen of two immunotherapies

27-05-2014

US pharma major Bristol-Myers Squibb and Incyte Corp have set up a clinical trial collaboration to evaluate…

Bristol-Myers SquibbINCB24360IncyteLicensingnivolumabOncologyPharmaceuticalResearch

Bristol-Myers’ nivolumab receives US FDA Breakthrough Therapy designation for Hodgkin lymphoma

15-05-2014

The US Food and Drug Administration has granted US drug major Bristol-Myers Squibb’s investigational…

Bristol-Myers SquibbnivolumabOncologyPharmaceuticalRegulationUSA

Bristol-Myers and Celldex to evaluate nivolumab and varlilumab combo

14-05-2014

US drug major Bristol-Myers Squibb and biotech firm Celldex Therapeutics have entered into a clinical…

BiotechnologyBristol-Myers SquibbCelldex TherapeuticsnivolumabOncologyResearchvarlilumab

Ono Pharma files for approval of nivolumab for melanoma in Japan

30-12-2013

Japanese drugmaker Ono Pharmaceutical has filed an application to obtain a manufacturing and marketing…

Asia-PacificBristol-Myers SquibbnivolumabOncologyOno PharmaceuticalPharmaceuticalRegulation

Positive new data on Bristol-Myers’s clazakizumab and nivolumab

Positive new data on Bristol-Myers’s clazakizumab and nivolumab

29-10-2013

US drug major Bristol-Myers Squibb and partner privately-held Alder Biopharmaceuticals have presented…

Alder BiopharmaceuticalsAnti-Arthritics/RheumaticsBristol-Myers SquibbclazakizumabnivolumabOncologyPharmaceuticalResearch

B-MS' nivolumab to lead NSCLC market with sales of $1.75 billion by 2022, says GlobalData

08-07-2013

US pharma major Bristol-Myers Squibb's (NYSE: BMY) nivolumab will overtake proven blockbuster competitors…

Bristol-Myers SquibbGlobalMarkets & MarketingnivolumabOncologyPharmaceutical

Bristol-Myers' data on Yervoy and nivolumab causes a stir

17-05-2013

Release of abstracts of presentations to be made at the forthcoming49th Annual Meeting of the American…

Bristol-Myers SquibbnivolumabOncologyPharmaceuticalResearchYervoy

Prognosis for renal cell carcinoma market development

27-11-2012

Through 2021, small-molecule angiogenesis inhibitors will dominate the renal cell carcinoma (RCC) drug…

Bristol-Myers SquibbGlaxoSmithKlineGlobalMarkets & MarketingnivolumabOncologyPfizerPharmaceuticalSutentVotrient

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top